200 related articles for article (PubMed ID: 29496324)
1. Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
Oda K; Kato K; Nakamura M; Jotatsu T; Noguchi S; Kawanami T; Kido T; Yatera K
Lung Cancer; 2018 Apr; 118():171-172. PubMed ID: 29496324
[No Abstract] [Full Text] [Related]
2. A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.
Feng Y; Chen C; Zhao L; Zhu X; Zhu X; Li Q
BMC Pulm Med; 2021 Sep; 21(1):291. PubMed ID: 34521373
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
[TBL] [Abstract][Full Text] [Related]
4. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
[TBL] [Abstract][Full Text] [Related]
5. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
Ciccarese C; Iacovelli R; Bria E; Modena A; Massari F; Brunelli M; Fantinel E; Bimbatti D; Zamboni GA; Artibani W; Tortora G
Immunotherapy; 2017 Jun; 9(7):579-587. PubMed ID: 28595514
[TBL] [Abstract][Full Text] [Related]
6. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
7. Hypothalamic expression of PD-L1: does it mediate hypothalamitis?
Iervasi E; Strangio A; Saverino D
Cell Mol Immunol; 2019 Jun; 16(6):625-626. PubMed ID: 30979971
[No Abstract] [Full Text] [Related]
8. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
[TBL] [Abstract][Full Text] [Related]
9. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
11. Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Oltolini C; Ripa M; Andolina A; Brioschi E; Cilla M; Petrella G; Gregorc V; Castiglioni B; Tassan Din C; Scarpellini P
Mycopathologia; 2019 Feb; 184(1):181-185. PubMed ID: 30101407
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors and response analysis: a tough challenge. A case report.
Bearz A; Perin T; Cancian L; Berto E; Sartor I; Tirelli U
BMC Res Notes; 2016 Jul; 9():349. PubMed ID: 27431235
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.
Naqash AR; Yang LV; Sanderlin EJ; Atwell DC; Walker PR
Acta Oncol; 2018 May; 57(5):705-708. PubMed ID: 29171332
[No Abstract] [Full Text] [Related]
14. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
[No Abstract] [Full Text] [Related]
15. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Jabkowski J; Loidl A; Auinger B; Kehrer H; Sepp N; Pichler R
Front Immunol; 2021; 12():606056. PubMed ID: 34220792
[TBL] [Abstract][Full Text] [Related]
17. Managing adverse effects of immunotherapy.
Gerson JN; Ramamurthy C; Borghaei H
Clin Adv Hematol Oncol; 2018 May; 16(5):364-374. PubMed ID: 29851932
[TBL] [Abstract][Full Text] [Related]
18. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
Robinson SD; Lai C; Hotton G; Anand G
Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-induced pneumonitis: cases report.
Helber HA; Hada AL; Pio RB; Moraes PHZ; Gomes DBD
Einstein (Sao Paulo); 2018 Jun; 16(2):eRC4030. PubMed ID: 29947645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
